Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | Nivo + ipi in RCC: OMNIVORE

Rana McKay • 28 May 2020
ASCO 2020
Genitourinary Cancer Kidney Cancer Ipilimumab Nivolumab
OMNIVORE

Rana R. McKay, MD, UC San Diego Health, La Jolla, CA, USA, highlights data coming from the OMNIVORE study (NCT03203473). This phase II reponse-based study looked at the optimized management of nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma (RCC). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Rana McKay

5:10
CheckMate 214: patterns of progression with nivolumab plus ipilimumab versus sunitinib for RCC
Rana McKay • 17 Feb 2021
3:53
Homologous recombination repair pathway alterations in mHSPC
Rana McKay • 17 Feb 2021
5:41
Biomarker analysis of olaparib with or without cediranib in mCRPC
Rana McKay • 17 Feb 2021
11:22
Neoadjuvant androgen deprivation therapy in men with high-risk localized prostate cancer
Rana McKay • 28 May 2020

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
0:45
SYNC-T combination immunotherapy in mCRPC
George Prendergast • 8 Apr 2024
0:40
PSMA PET findings in 225AC-J591-treated patients with mCRPC
Andres Ricaurte-Fajardo • 9 Apr 2024
0:45
Should radioligand therapies be used in earlier settings in prostate cancer?
Andres Ricaurte-Fajardo • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals